Overnight
Outlook Therapeutics
Biopharmaceutical
We are a late clinical-stage biopharmaceutical company working to develop the first ophthalmic formulation of bevacizumab approved by the U.S. Food and Drug Administration, or FDA, for use in retinal indications.
Symbol
OTLK
Last Closing Price
$1.22
Anticipated Date
January 29, 2021
Underwriters
H.C. WAINWRIGHT & CO., INC.
This offering is no longer available
Sign Up to participate in future offerings
To view the prospectus for Outlook Therapeutics, or any offering listed on ClickIPO,
download the ClickIPO app...
or a prospectus can be requested from G. Price at
ClickIPO Securities, LLC P. O. Box 21154, Mesa, AZ 85277